Landscapes / Targets
CD47
15 drugs act on CD47, in 30 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs15
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Akeso · Public 9926.HK |
Phase 3 | 30 Dec 2026Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Myelodysplastic Syndrome, Acute Myeloid Leukemia and 10 more | ||||
| Open drug page | |||||
IMC002not checked |
— |
Phase 3 | 31 May 2027Phase 3 trial completes | ||
| Next date | 31 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Gastric Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 2 | 1 Apr 2027Phase 2 trial completes | |||
| Next date | 1 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | B-cell Non Hodgkin Lymphoma, Primary Membranous Nephropathy | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Sanofi · Public SNY |
Phase 1/2 | 13 Sep 2027Phase 1/2 trial completes | ||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | 13 Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Plasma Cell Myeloma Refractory | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Phase 2 | Dec 2027Phase 2 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2027Phase 1/2 trial completes | |||
| Next date | 31 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Biliary Tract Cancer, Melanoma | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) and 4 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 1 Jan 2028Phase 1/2 trial completes | |||
| Next date | 1 Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma and 1 more | ||||
| Open drug page | |||||
— |
ImmuneOnco · Public 1541.HK |
Phase 1/2 | Feb 2029Phase 1/2 trial completes | ||
| Next date | Feb 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Jun 2027Phase 1 trial completes | |||
| Next date | 30 Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Metastatic Pancreatic Cancer, Unresectable Colorectal Cancer | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Dec 2027Phase 1 trial completes | |||
| Next date | 30 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Cancer | ||||
| Open drug page | |||||
— |
3SBio · Public 1530.HK |
Phase 1 | 30 Mar 2028Phase 1 trial completes | ||
| Next date | 30 Mar 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors Patients | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Pfizer · Public PFE |
Phase 1 | — | ||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
TQB2928not checked |
— |
Phase 1 | — | ||
| Also tested for | Advanced Non-small Cell Lung Cancer | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 13 of 15 drugs. The other 2 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026